Please login to the form below

Not currently logged in

Valeant buys Sanofi's dermatology unit

Sanofi has said it is to sell its Dermik dermatology unit to Canada-based Valeant Pharmaceuticals for $425m

Sanofi has said it is to sell its Dermik dermatology unit to Canada-based Valeant Pharmaceuticals for $425m.

Dermik operates in the US and Canada, and has a portfolio that includes Benzaclin (benzoyl peroxide/clindamycin) for the treatment of acne; Carac (fluorouracil cream) for the treatment of keratoses; and Sculptra (poly-L-lactic acid), a facial injectable for wrinkles.

Valeant will obtain all Dermik assets, including available inventories of approximately $18m, which consist of an aesthetic and therapeutic business in the United States and Canada, as well as a widely dispersed aesthetic business around the world.

Valeant will also acquire Sanofi's manufacturing site in Laval, Canada.

Sanofi said it has decided to sell its dermatology business to concentrate on other areas of growth.

"This divestiture allows us to rationalise our portfolio and improve focus on our core businesses," said Christopher A Viehbacher, CEO, Sanofi. "Our manufacturing operations in Laval and our field operations teams will benefit from Valeant's stronger presence in dermatology."

11th July 2011


Featured jobs

Subscribe to our email news alerts


Add my company
Merrill Brink International

Merrill Brink International is a leading provider of life sciences, legal, financial, manufacturing and corporate language solutions for global companies....

Latest intelligence

RWE Blog 3: Is real-world evidence the holy grail
We began our four-blog series by evaluating the role of real-world data (RWD) and real-world-evidence (RWE) in Real-world challenges and real-world data, and understanding the payer's perspective, in Payers use...
What do Healthcare Professionals think about the inclusion of remote selling techniques?
Evolving to a digitally focused pharma / healthcare company - an organisational roadmap...
Drug pricing and competition
Strengthening business competition and reducing anti-competitive practices
How the CMA is tackling high prices for essential drugs...